Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 18 · below the Ichimoku cloud · RSI 38 · MACD above its signal
| 10.00 | 52-week high | +1393.88% |
| 1.04 | Previous month high | +55.36% |
| 0.8000 | Previous week high | +19.51% |
| 0.7251 | R3 (classic) | +8.33% |
| 0.7105 | R2 (classic) | +6.13% |
| 0.7100 | Previous week low | +6.07% |
| 0.6958 | Previous day high | +3.94% |
| 0.6899 | R1 (classic) | +3.07% |
| 0.6753 | Pivot | +0.88% |
| 0.6694 | Price now | |
| 0.6606 | Previous day low | −1.31% |
| 0.6547 | S1 (classic) | −2.19% |
| 0.6401 | S2 (classic) | −4.38% |
| 0.6320 | Previous month low | −5.59% |
| 0.6195 | S3 (classic) | −7.45% |
| 0.5500 | 52-week low | −17.84% |
None of the 29 investors followed here reported a position in GNTA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GNTA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -33.8 | 0.5 | -32.2 | 5.8 | 44.9 | 78.6 | -19.0 | -31.5 | -31.4 | -4.4 | −55.1% | ||
| 2025 | -19.1 | 10.8 | 1.8 | -2.0 | 15.7 | -32.3 | 26.3 | -2.2 | -15.4 | -19.2 | -21.8 | -25.9 | −65.7% |
| 2024 | -18.6 | 9.3 | -20.5 | -12.0 | 3.6 | -2.8 | 38.7 | -10.0 | 10.3 | 19.4 | 2.0 | -16.3 | −12.1% |
| 2023 | 11.6 | 5.9 | -11.5 | 4.3 | 1.7 | -3.4 | -7.7 | 6.6 | -11.2 | 3.7 | -2.6 | -4.8 | −10.0% |
| 2022 | -23.4 | -21.9 | 6.7 | -17.1 | 42.4 | -15.0 | -6.4 | -9.9 | -15.9 | -11.6 | 18.5 | 5.5 | −49.8% |
| 2021 | — |
No insider transactions reported for GNTA.
No analyst coverage for this instrument.
Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors. Its activities and acquisition strategy covers aerospace, defense, national security, and biotechnology/biosecurity. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.